peptide confessions

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

What is tesamorelin?

Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue that prompts the pituitary to release growth hormone. In the US it is FDA-approved as Egrifta WR only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states it is not indicated for weight-loss management because it is weight-neutral. As of 11 November 2026 this hub lists 35 published reports. This is not a dosing recommendation.

What the research says

In two 26-week placebo-controlled trials in 816 adults with HIV lipodystrophy, visceral (deep belly) fat fell about 18% and 14% with tesamorelin, with little change in overall body weight. Long-term cardiovascular safety has not been established. Label warnings include raised IGF-1, fluid retention (swelling, joint pain, carpal tunnel symptoms), glucose intolerance or diabetes, and injection-site reactions. Evidence in people without HIV is limited.

Health Canada issued a Notice of Compliance for Egrifta in 2014 for excess visceral fat in treatment-experienced adults with HIV lipodystrophy. The Drug Product Database later listed both DINs as cancelled (post-market, 30 September 2022, and pre-market, 13 July 2023), and no tesamorelin product is currently marketed in Canada. Tesamorelin is named on the 2026 WADA Prohibited List under S2.2.4 (growth hormone-releasing factors) and is prohibited at all times in sport, including where a therapeutic product exists. Last reviewed: November 11, 2026.

What tesamorelin confessions describe

Writers often say the scale did not move while their waist shrank (#295), consistent with its effect on visceral fat. Others describe slow belly-fat change with unexpected skin effects (#211) or an improvement in anxiety they attribute to it (#356).

Negative accounts include whole-body tingling and vomiting in the first week (#380) and a hospital stay for very low blood sugar after combining it with ipamorelin (#746). These are anonymous accounts, not evidence. Related: tesamorelin side effects and tesamorelin results.

Anonymous tesamorelin reports

If you have used tesamorelin, prescribed or not, submit what happened.

Submit yours

Community Q&A

Is tesamorelin FDA approved?
Yes, as Egrifta WR, but only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss drug.
Is tesamorelin available in Canada?
Health Canada authorized Egrifta in 2014 for a narrow HIV lipodystrophy indication. Both Drug Product Database DINs were later cancelled, and no tesamorelin product is currently marketed in Canada.
Does tesamorelin cause weight loss?
Not much overall: the US label calls it weight-neutral. In trials it reduced visceral belly fat by roughly 14% to 18% over 26 weeks.
Is tesamorelin banned in sport?
Yes. It is named under WADA S2.2.4 and is prohibited at all times, even though an approved therapeutic product exists in some countries.
What are tesamorelin's main side effects?
The label lists joint pain, swelling, injection-site reactions, muscle pain, raised IGF-1 and possible glucose intolerance or diabetes.
How many tesamorelin reports are on this site?
As of 11 November 2026, this hub lists 35 published reports. The heading count updates as new reports are published.
Does this page give dosing or sourcing advice?
No. This is not a dosing recommendation.

Sources

  1. Egrifta WR (tesamorelin) prescribing information — DailyMed (NLM)

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.

the week's best confessions, in your inbox.